ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
67.54
+1.13 (+1.70%)
At close: 4:00PM EDT

67.89 +0.35 (0.52%)
After hours: 7:15PM EDT

Stock chart is not supported by your current browser
Previous Close66.56
Open67.34
Bid67.80 x 800
Ask67.90 x 1300
Day's Range66.60 - 67.92
52 Week Range62.66 - 98.70
Volume7,601,317
Avg. Volume10,491,584
Market Cap99.857B
Beta (3Y Monthly)0.69
PE Ratio (TTM)24.66
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield4.28 (6.44%)
Ex-Dividend Date2019-07-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • Synlogic Discontinues Development of SYNB1020, Stock Down
    Zacks

    Synlogic Discontinues Development of SYNB1020, Stock Down

    Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

  • Barrons.com

    AbbVie Stock Slipped to a New Low, and One Exec Scooped Up Shares

    Jeffrey Ryan Stewart, the biopharmaceutical firm’s senior vice president of U.S. commercial operations, paid $1 million last week for stock trading near a 2½-year low.

  • Pot Entrepreneurs Can Now Get an MBA in Cannabis
    Investopedia

    Pot Entrepreneurs Can Now Get an MBA in Cannabis

    USciences says its program is first-of-its-kind and is offered as a track under the specialized pharma and healthcare MBA.

  • Bayer Sells Animal Health Division to Elanco: Now What?
    Zacks

    Bayer Sells Animal Health Division to Elanco: Now What?

    On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

  • Barrons.com

    Buy AbbVie Stock Because You ‘Can’t Ignore’ How Cheap It Is

    Piper Jaffray argues the worst may finally be over for beleaguered AbbVie stock, and its price looks especially attractive.

  • Here's Why Allergan is Outperforming Its Industry Of Late
    Zacks

    Here's Why Allergan is Outperforming Its Industry Of Late

    Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

  • AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
    Motley Fool

    AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

    The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.

  • High-Dividend Stocks on Historic Discount as Yields Plunge, says Goldman
    Investopedia

    High-Dividend Stocks on Historic Discount as Yields Plunge, says Goldman

    U.S. high-dividend stocks are trading at their biggest discount in four decades as investors flock to bonds, pushing down their yields.

  • Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks?
    Investor's Business Daily

    Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks?

    Looking for stocks to buy? Get analysis of large-cap stocks like Amazon, Alibaba and Dow Jones stocks GE and Microsoft to see if it's time to buy — or sell.

  • AbbVie Rises 3%
    Investing.com

    AbbVie Rises 3%

    Investing.com - AbbVie (NYSE:ABBV) rose by 3.05% to trade at $66.39 by 12:56 (16:56 GMT) on Monday on the NYSE exchange.

  • AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
    Zacks

    AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

    AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit
    Investor's Business Daily

    How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit

    Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.

  • How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals
    Investor's Business Daily

    How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals

    Merck stock jumped Friday after an analyst initiated coverage of the Dow Jones pharma giant with an outperform rating, citing "the Keytruda wave." Keytruda is a blockbuster cancer drug.

  • MarketWatch

    FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA

    The U.S. Food and Drug Administration has approved AbbVie Inc's Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate hasn't worked, AbbVie announced Friday. The pharmaceutical company said Rinvoq should be available in the U.S. later this month. "Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity - the primary treatment goals for rheumatoid arthritis," said Roy Fleischmann, a clinical professor at the University of Texas Southwestern Medical Center at Dallas who led one of AbbVie's clinical trials of Rinvoq. "With this FDA approval, Rinvoq has the potential to help additional people living with RA achieve remission who have not yet reached this goal." The European Medicines Agency and regulatory authorities in Canada and Japan are still reviewing the drug. Shares of AbbVie were up 2.2% Friday afternoon, though they've fallen 30% in the year to date amid investor worry over declining sales of the company's blockbuster drug Humira. The stock also took a hit in June when the AbbVie said it would be acquiring Botox-maker Allergan Plc in a deal worth around $63 billion. The S&P 500 has gained 15.2% so far this year.

  • AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

    AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Reuters

    UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr

    AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. A four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year. Humira brought in global revenue of $4.87 billion in the second quarter, but sales have been hit by competition from cheaper rivals in Europe, and AbbVie in June announced a deal to buy Botox-maker Allergan Plc for $63 billion to reduce dependence on the drug.

  • Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
    Zacks

    Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe

    The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.

  • The Top Pharma Stocks for 2019
    Investopedia

    The Top Pharma Stocks for 2019

    Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.

  • 13 High-Yield Dividend Stocks to Watch
    Kiplinger

    13 High-Yield Dividend Stocks to Watch

    High-yield dividend stocks have gained even more allure lately in the face of shrinking bond yields. However, while a handful are ready buys right now, several more sport alluring yields - at least 5%, and up into the double digits - but need a little more time to simmer before it's time to dip in.Patience is a virtue in life. That's particularly true in the investing world. It's even true across investing disciplines. Sober value investors wait for their price before buying, but disciplined market technicians also know to wait for the proper setup before trading.Sometimes, you need to wait for a fundamental catalyst to make your trade worth making. Other times, it's simply a matter of waiting for the right price. But the key is having the self-control to wait for your moment. Lack of patience can be a portfolio killer."We tell our clients during the onboarding process that we won't be investing their entire portfolio on day one," explains Chase Robertson, Managing Partner of Houston-based RIA Robertson Wealth Management. "We tend to average into our portfolios over time as market conditions warrant, and we're not opposed to having large cash positions. Our clients thank us in the end."Today, we're going to look at 13 high-yield dividend stocks to keep on your watch list. All are stocks yielding over 5% that you probably could buy today, but all have their own unique quirks that might make it more prudent to watch them a little longer rather than jump in with both feet. SEE ALSO: 57 Dividend Stocks You Can Count On in 2019

  • 5 Top Cancer-Fighting Stocks to Buy Now
    Motley Fool

    5 Top Cancer-Fighting Stocks to Buy Now

    Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

  • How Tesla has Become Most Profitable Short Bet at $2.75 Billion
    Investopedia

    How Tesla has Become Most Profitable Short Bet at $2.75 Billion

    Tesla short sellers may reap even bigger profits if CEO Musk fails to revive the electric car company.

  • Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
    Zacks

    Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

    Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.

  • Financial Times

    Correction: Allergan sale

    Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...

  • Morningstar

    Defensive Stocks on Sale

    Recession worries have once again gripped the stock market. U.S. bond yields are falling, the yield curve is inverting, and pundits are prognosticating. Of course, Morningstar isn't in the business of predicting where the market is headed.